HAE · Haemonetics Corp
$107.71
-1.09 (-1.00%)
At close · Aug 24
Market Cap
$4.95B
Shares
45.50M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.33B
-2%
FY2026
Net Income
$97.31M
-42%
FY2026
Gross Margin
59.04%
+4pp
FY2026
Operating Margin
11.75%
-4.6pp
FY2026
Diluted EPS
$2.05
-38.1%
FY2026
Operating Cash Flow
$293.22M
+61.4%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.35B | $1.33B | $1.36B | $1.31B | $1.17B | $993.2M | $870.46M | $988.48M | $967.58M | $903.92M | $886.12M | — | $910.37M | $938.51M | $891.99M | $727.84M | $676.69M | $645.43M | — | |
| $553.87M | $546.44M | $611.87M | $617.51M | $553.56M | $487.69M | $472.63M | $503.97M | $550.04M | $492.02M | $507.62M | $502.92M | $475.96M | $470.14M | $463.86M | $358.6M | $321.49M | $307.95M | $289.71M | |
| $798.15M | $787.59M | $748.96M | $691.55M | $615.1M | $505.5M | $397.84M | $484.51M | $417.54M | $411.91M | $378.49M | $405.91M | $434.42M | $468.37M | $428.13M | $369.24M | $355.21M | $337.48M | $308.17M | |
| — | 59.04% | 55.04% | 52.83% | 52.63% | 50.9% | 45.7% | 49.02% | 43.15% | 45.57% | 42.71% | — | 47.72% | 49.91% | 48% | 50.73% | 52.49% | 52.29% | — | |
| $59.71M | $59.77M | $62.72M | $54.44M | $50.13M | $46.8M | $32.86M | $30.88M | $35.71M | $39.23M | $37.56M | $44.97M | $54.19M | $54.2M | $44.39M | $36.8M | $32.66M | $26.38M | $23.86M | |
| $450.64M | $442.42M | $436.79M | $429.78M | $376.68M | $340.14M | $275.22M | $282.02M | $273.47M | $316.52M | $301.73M | $317.22M | $337.17M | $365.98M | $323.05M | $243.68M | $213.9M | $214.48M | $198.74M | |
| $49M | $50.5M | $55.6M | $41.4M | $42.1M | $56.6M | $41.2M | $34.2M | $24.8M | $31.9M | $37.2M | $59.3M | $33.5M | $29.2M | $22.1M | $11.4M | $11.1M | $7.7M | — | |
| $110.07M | $111.72M | $115.59M | $97.22M | $93.31M | $97.75M | $84.29M | $110.29M | $109.42M | $89.25M | $89.73M | $89.91M | $86.05M | $81.74M | $65.48M | $49.97M | $48.15M | $43.24M | $36.46M | |
| $4.15M | $3.11M | $13.91M | $14.09M | $657K | $4.23M | $1.44M | $3.59M | $395K | $30.53M | $21.83M | $23.06M | $36.86M | $49.05M | $10.89M | $5.86M | $4.48M | — | — | |
| $637.83M | $630.85M | $527.14M | $526.67M | $459.06M | $424.75M | $308.09M | $381.16M | $333.99M | $355.75M | $397.88M | $449.86M | $393.88M | $421.93M | $371.69M | $280.48M | $244.66M | $254.2M | $222.6M | |
| $160.32M | $156.73M | $221.82M | $164.88M | $156.03M | $80.75M | $89.75M | $103.35M | $83.55M | $56.16M | -$19.38M | -$43.94M | $40.54M | $46.43M | $56.44M | $88.76M | $110.55M | $83.28M | $85.57M | |
| — | 11.75% | 16.3% | 12.6% | 13.35% | 8.13% | 10.31% | 10.46% | 8.63% | 6.21% | -2.19% | — | 4.45% | 4.95% | 6.33% | 12.19% | 16.34% | 12.9% | — | |
| $270.39M | $268.45M | $337.4M | $262.1M | $249.34M | $178.5M | $174.03M | $213.64M | $192.96M | $145.4M | $70.35M | $45.97M | $126.59M | $128.17M | $121.92M | $138.72M | $158.69M | $126.52M | $122.03M | |
| -$41K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $6000 | $742K | $64K | |
| $388K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $384K | $399K | $1.97M | |
| -$29.89M | -$28.7M | -$9.75M | -$13.02M | -$14.63M | -$17.12M | -$16.83M | -$16.2M | -$9.91M | -$4.53M | -$8.1M | -$9.47M | -$9.38M | -$10.03M | -$6.54M | $740K | -$467K | -$2.01M | -$2.47M | |
| — | — | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $130.44M | $128.03M | $212.07M | $151.87M | $141.4M | $63.63M | $72.91M | $87.15M | $73.63M | $59.63M | -$27.48M | -$53.42M | $31.17M | $36.4M | $49.9M | $89.5M | $110.08M | $81.27M | $85M | |
| $34.15M | $30.72M | $44.39M | $34.31M | $26M | $20.25M | -$6.56M | $10.63M | $18.61M | $14.06M | -$1.21M | $2.16M | $14.27M | $1.25M | $11.1M | $22.61M | $30.1M | $22.9M | $25.7M | |
| $96.29M | $97.31M | $167.68M | $117.56M | $115.4M | $43.38M | $79.47M | $76.53M | $55.02M | $45.57M | -$26.27M | -$55.58M | $16.9M | $35.15M | $38.8M | $66.89M | $79.98M | $58.37M | $59.3M | |
| — | 7.29% | 12.32% | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | 5.69% | 5.04% | -2.96% | — | 1.86% | 3.75% | 4.35% | 9.19% | 11.82% | 9.04% | — | |
| $90.9M | $114.78M | $148.23M | $112.31M | $110.97M | $46.97M | $95.06M | $61.77M | $43.63M | $59.45M | -$24.1M | -$68.9M | -$6.24M | $31.13M | $35.12M | $66.46M | $83.62M | — | — | |
| USD/shares | — | $2.06 | $3.33 | $2.32 | $2.27 | $0.85 | $1.57 | $1.51 | $1.07 | $0.86 | -$0.51 | -$1.09 | $0.33 | $0.68 | $0.76 | $1.32 | $1.59 | $2.29 | $2.34 |
| USD/shares | — | $2.05G | $3.31 | $2.29G | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | -$0.51 | -$1.09 | $0.32 | $0.67 | $0.74 | $1.30 | $1.56 | $2.24 | $2.27 |
| shares | — | 47.18M | 50.33M | 50.71M | 50.78M | 51.05M | 50.69M | 50.69M | 51.53M | 52.76M | 51.52M | 50.91M | 51.53M | 51.61M | 51.35M | 50.73M | 50.15M | 25.45M | 25.39M |
| shares | — | 47.35M | 50.73M | 51.4M | 51.42M | 51.35M | 51.29M | 51.82M | 52.94M | 53.5M | 51.52M | 50.91M | 52.09M | 52.38M | 52.26M | 51.59M | 51.19M | 26.06M | 26.17M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2026: $1.26B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
4.36×
Peer median 3.10×
EV/EBIT
36.81×
Peer median 21.93×
P/E (TTM)
—
Peer median 30.00×
Peer medians compare against the 44 similar-size Medical Devices companies (of 145 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Hospital | $588,304,000 | $564,269,000 | $456,289,000 | $381,710,000 | — |
| Plasma | $524,456,000 | $535,431,000 | $569,535,000 | $499,916,000 | — |
| Blood Center | $221,267,000 | $261,124,000 | $283,231,000 | $287,034,000 | — |
| Business Unit | — | — | — | — | $972,663,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $982,176,000 | $1,010,918,000 | $970,007,000 | $842,897,000 | $639,322,000 | $522,607,000 | $646,204,000 | $606,845,000 |
| Europe | $185,019,000 | $175,655,000 | $160,142,000 | $156,680,000 | $163,520,000 | $159,077,000 | $153,347,000 | $164,504,000 |
| Asia | $87,212,000 | $92,305,000 | $107,536,000 | $104,135,000 | $110,802,000 | $105,820,000 | $109,295,000 | $118,700,000 |
| Japan | $68,200,000 | $62,408,000 | $58,087,000 | $61,295,000 | $75,562,000 | $77,676,000 | $72,218,000 | $69,908,000 |
| Other Country or Region | $11,420,000 | $19,538,000 | $13,283,000 | $3,653,000 | $3,990,000 | $5,283,000 | $7,415,000 | $7,622,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Hospital Products and Services | $588,304,000 | $564,269,000 | $456,289,000 | — | — | — | — | — |
| Blood Center Products and Services | $221,267,000 | $261,124,000 | $283,231,000 | — | — | — | — | — |
| Blood Center | — | — | — | $226,819,000 | $236,158,000 | $239,614,000 | $252,829,000 | $269,203,000 |
| Hospital | — | — | — | $378,107,000 | $329,427,000 | $216,583,000 | $198,419,000 | $196,539,000 |
| Plasma | — | — | — | $563,734,000 | $427,611,000 | $414,266,000 | $537,231,000 | $501,837,000 |
| Service | — | — | $21,605,000 | $20,044,000 | $20,533,000 | $20,758,000 | $19,830,000 | $19,906,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Plasma | $184,795,000 | $184,510,000 | $181,967,000 | $124,746,000 | $183,131,000 | $172,463,000 | $225,351,000 | $180,300,000 |
| Hospital | $103,735,000 | $88,975,000 | $52,198,000 | $29,415,000 | $129,783,000 | $84,066,000 | $80,669,000 | — |
| Blood Center | $49,976,000 | $52,819,000 | $42,372,000 | $64,272,000 | $136,691,000 | $141,962,000 | $159,802,000 | $163,628,000 |
| Japan | — | — | — | — | — | — | $225,351,000 | $180,300,000 |
| Americas Blood Center and Hospital and Asia Pacific | — | — | — | — | — | $84,066,000 | $80,669,000 | $76,338,000 |
| EMEA | — | — | — | — | — | — | $159,802,000 | $163,628,000 |
Operating Margin by Segment (%)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Hospital | 17.6% | 15.8% | 11.4% | 7.7% |
| Plasma | 35.2% | 34.5% | 32% | 25% |
| Blood Center | 22.6% | 20.2% | 15% | 22.4% |
Key facts
CIK
313143
CUSIP
405024100
13F (30d)
279 filings
272 filers
Visit website
Investor relations